-
1
-
-
33646345152
-
KDOQI: Clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease
-
National Kidney Foundation
-
National Kidney Foundation. KDOQI: clinical practice guidelines and clinical practice recommendations for anemia in chronic kidney disease. Am J Kidney Dis 2006; 47(Suppl 3): S1-S146.
-
(2006)
Am J Kidney Dis
, vol.47
, Issue.SUPPL. 3
-
-
-
2
-
-
0038806683
-
The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients
-
Tonelli M, Winkelmayer WC, Jindal KK et al. The cost-effectiveness of maintaining higher hemoglobin targets with erythropoietin in hemodialysis patients. Kidney Int 2003; 64: 295-304.
-
(2003)
Kidney Int
, vol.64
, pp. 295-304
-
-
Tonelli, M.1
Winkelmayer, W.C.2
Jindal, K.K.3
-
3
-
-
0028117942
-
Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients
-
Roth D, Smith RD, Schulman G et al. Effects of recombinant human erythropoietin on renal function in chronic renal failure predialysis patients. Am J Kidney Dis 1994; 24: 777-784.
-
(1994)
Am J Kidney Dis
, vol.24
, pp. 777-784
-
-
Roth, D.1
Smith, R.D.2
Schulman, G.3
-
4
-
-
0028945387
-
Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients
-
Revicki DA, Brown RE, Feeny DH et al. Health-related quality of life associated with recombinant human erythropoietin therapy for predialysis chronic renal disease patients. Am J Kidney Dis 1995; 25: 548-554.
-
(1995)
Am J Kidney Dis
, vol.25
, pp. 548-554
-
-
Revicki, D.A.1
Brown, R.E.2
Feeny, D.H.3
-
5
-
-
0025373361
-
Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis
-
Canadian Erythropoietin Study Group
-
Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. BMJ 1990; 300: 573-578.
-
(1990)
BMJ
, vol.300
, pp. 573-578
-
-
-
6
-
-
27144498003
-
Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease
-
Parfrey PS, Foley RN, Wittreich BH et al. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. J Am Soc Nephrol 2005; 16: 2180-2189.
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 2180-2189
-
-
Parfrey, P.S.1
Foley, R.N.2
Wittreich, B.H.3
-
7
-
-
0033857652
-
Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy
-
Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58: 1325-1335.
-
(2000)
Kidney Int
, vol.58
, pp. 1325-1335
-
-
Foley, R.N.1
Parfrey, P.S.2
Morgan, J.3
-
8
-
-
9144239992
-
Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): Results of a randomized clinical trial
-
Roger SD, McMahon LP, Clarkson A et al. Effects of early and late intervention with epoetin alpha on left ventricular mass among patients with chronic kidney disease (stage 3 or 4): results of a randomized clinical trial. J Am Soc Nephrol 2004; 15: 148-156.
-
(2004)
J Am Soc Nephrol
, vol.15
, pp. 148-156
-
-
Roger, S.D.1
McMahon, L.P.2
Clarkson, A.3
-
9
-
-
27144539133
-
Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD
-
Levin A, Djurdjev O, Thompson C et al. Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005; 46: 799-811.
-
(2005)
Am J Kidney Dis
, vol.46
, pp. 799-811
-
-
Levin, A.1
Djurdjev, O.2
Thompson, C.3
-
10
-
-
33846642617
-
Target level for hemoglobin correction in patients with diabetes and CKD: Primary results of the Anemia Correction in Diabetes (ACORD) Study
-
Ritz E, Laville M, Bilous RW et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am J Kidney Dis 2007; 49: 194-207.
-
(2007)
Am J Kidney Dis
, vol.49
, pp. 194-207
-
-
Ritz, E.1
Laville, M.2
Bilous, R.W.3
-
11
-
-
33751002326
-
Normalization of hemoglobin level in patients with chronic kidney disease and anemia
-
Drueke T, Locatelli F, Clyne N et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355: 2071-2084.
-
(2006)
N Engl J Med
, vol.355
, pp. 2071-2084
-
-
Drueke, T.1
Locatelli, F.2
Clyne, N.3
-
12
-
-
33750983605
-
Correction of anemia with epoetin alpha in chronic kidney disease
-
Singh A, Szczech L, Tang KL et al. Correction of anemia with epoetin alpha in chronic kidney disease. N Engl J Med 2006; 355: 2085-2096.
-
(2006)
N Engl J Med
, vol.355
, pp. 2085-2096
-
-
Singh, A.1
Szczech, L.2
Tang, K.L.3
-
13
-
-
0032572913
-
The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin
-
Besarab A, Bolton WK, Browne JK et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339: 584-590.
-
(1998)
N Engl J Med
, vol.339
, pp. 584-590
-
-
Besarab, A.1
Bolton, W.K.2
Browne, J.K.3
-
14
-
-
0037317068
-
A randomized controlled trial of hemoglobin normalization with epoetin alfa in predialysis and dialysis patients
-
Furuland H, Linde T, Ahlmen J et al. A randomized controlled trial of hemoglobin normalization with epoetin alfa in predialysis and dialysis patients. Nephrol Dial Transplant 2003; 18: 353-361.
-
(2003)
Nephrol Dial Transplant
, vol.18
, pp. 353-361
-
-
Furuland, H.1
Linde, T.2
Ahlmen, J.3
-
15
-
-
48649110499
-
-
Food and Drug Administration. FDA Advisory Committee Briefing Document Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee: reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) administered for the treatment of anemia associated with chronic renal failure. In: Food and Drug Administration, Division of Medical Imaging and Hematology Products and Office of Surveillance and Epidemiology (OSE) (ed.), FDA: Rockville, MD, 2007.
-
Food and Drug Administration. FDA Advisory Committee Briefing Document Joint meeting of the Cardiovascular and Renal Drugs Advisory Committee and the Drug Safety and Risk Management Committee: reassessment of the Risks of Erythropoiesis-Stimulating Agents (ESAs) administered for the treatment of anemia associated with chronic renal failure. In: Food and Drug Administration, Division of Medical Imaging and Hematology Products and Office of Surveillance and Epidemiology (OSE) (ed.), FDA: Rockville, MD, 2007.
-
-
-
-
16
-
-
33846669860
-
Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: A meta-analysis
-
Phrommintikul A, Haas SJ, Elsik M et al. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 2007; 369: 381-388.
-
(2007)
Lancet
, vol.369
, pp. 381-388
-
-
Phrommintikul, A.1
Haas, S.J.2
Elsik, M.3
-
17
-
-
0029151422
-
Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients
-
Albitar S, Meulders Q, Hammoud H et al. Subcutaneous versus intravenous administration of erythropoietin improves its efficiency for the treatment of anaemia in haemodialysis patients. Nephrol Dial Transplant 1995; 10(Suppl 6): 40-43.
-
(1995)
Nephrol Dial Transplant
, vol.10
, Issue.SUPPL. 6
, pp. 40-43
-
-
Albitar, S.1
Meulders, Q.2
Hammoud, H.3
-
18
-
-
0036724273
-
Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients
-
Besarab A, Reyes CM, Hornberger J. Meta-analysis of subcutaneous versus intravenous epoetin in maintenance treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002; 40: 439-446.
-
(2002)
Am J Kidney Dis
, vol.40
, pp. 439-446
-
-
Besarab, A.1
Reyes, C.M.2
Hornberger, J.3
-
19
-
-
0030001078
-
Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin
-
Jensen JD, Madsen JK, Jensen LW. Comparison of dose requirement, serum erythropoietin and blood pressure following intravenous and subcutaneous erythropoietin treatment of dialysis patients. IV and SC erythropoietin. Eur J Clin Pharmacol 1996; 50: 171-177.
-
(1996)
Eur J Clin Pharmacol
, vol.50
, pp. 171-177
-
-
Jensen, J.D.1
Madsen, J.K.2
Jensen, L.W.3
-
20
-
-
0032572918
-
Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients
-
Kaufman JS, Reda DJ, Fye CL et al. Subcutaneous compared with intravenous epoetin in patients receiving hemodialysis. Department of Veterans Affairs Cooperative Study Group on Erythropoietin in Hemodialysis Patients. N Engl J Med 1998; 339: 578-583.
-
(1998)
N Engl J Med
, vol.339
, pp. 578-583
-
-
Kaufman, J.S.1
Reda, D.J.2
Fye, C.L.3
-
21
-
-
0031067025
-
Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients
-
Parker KP, Mitch WE, Stivelman JC et al. Safety and efficacy of low-dose subcutaneous erythropoietin in hemodialysis patients. J Am Soc Nephrol 1997; 8: 288-293.
-
(1997)
J Am Soc Nephrol
, vol.8
, pp. 288-293
-
-
Parker, K.P.1
Mitch, W.E.2
Stivelman, J.C.3
-
22
-
-
0026543474
-
Cost benefits of low dose subcutaneous erythropoietin in patients with anemia of end stage renal disease
-
Stevens ME, Summerfield GP, Hall AA et al. Cost benefits of low dose subcutaneous erythropoietin in patients with anemia of end stage renal disease. BMJ 1992; 304: 474-477.
-
(1992)
BMJ
, vol.304
, pp. 474-477
-
-
Stevens, M.E.1
Summerfield, G.P.2
Hall, A.A.3
-
23
-
-
0026565505
-
Crossover comparison of intravenous and subcutaneous erythropoietin in hemodialysis patients
-
Tomson CR, Feehally J, Walls J. Crossover comparison of intravenous and subcutaneous erythropoietin in hemodialysis patients. Nephrol Dial Transplant 1992; 7: 129-132.
-
(1992)
Nephrol Dial Transplant
, vol.7
, pp. 129-132
-
-
Tomson, C.R.1
Feehally, J.2
Walls, J.3
-
24
-
-
23044449036
-
Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population
-
Vercaigne LM, Collins DM, Penner SB. Conversion from subcutaneous to intravenous erythropoietin in a hemodialysis population. J Clin Pharmacol 2005; 45: 895-900.
-
(2005)
J Clin Pharmacol
, vol.45
, pp. 895-900
-
-
Vercaigne, L.M.1
Collins, D.M.2
Penner, S.B.3
-
25
-
-
33144454609
-
Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis
-
Moist LM, Muirhead N, Wazny LD et al. Erythropoietin dose requirements when converting from subcutaneous to intravenous administration among patients on hemodialysis. Ann Pharmacother 2006; 40: 198-203.
-
(2006)
Ann Pharmacother
, vol.40
, pp. 198-203
-
-
Moist, L.M.1
Muirhead, N.2
Wazny, L.D.3
-
26
-
-
20844450196
-
Epoetin-induced autoimmune pure red cell aplasia
-
Casadevall N, Eckardt KU, Rossert J. Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol 2005; 16(Suppl 1): S67-S69.
-
(2005)
J Am Soc Nephrol
, vol.16
, Issue.SUPPL. 1
-
-
Casadevall, N.1
Eckardt, K.U.2
Rossert, J.3
-
27
-
-
19044392727
-
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes
-
Boven K, Stryker S, Knight J et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int 2005; 67: 2346-2353.
-
(2005)
Kidney Int
, vol.67
, pp. 2346-2353
-
-
Boven, K.1
Stryker, S.2
Knight, J.3
-
28
-
-
33646181084
-
Clinical implications of converting stable hemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa
-
Aarup M, Bryndum J, Dieperink H et al. Clinical implications of converting stable hemodialysis patients from subcutaneous to intravenous administration of darbepoetin alfa. Nephrol Dial Transplant 2006; 21: 1312-1316.
-
(2006)
Nephrol Dial Transplant
, vol.21
, pp. 1312-1316
-
-
Aarup, M.1
Bryndum, J.2
Dieperink, H.3
-
29
-
-
0037317083
-
Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo)
-
Locatelli F, Canaud B, Giacardy F et al. Treatment of anemia in dialysis patients with unit dosing of darbepoetin alfa at a reduced dose frequency relative to recombinant human erythropoietin (rHuEpo). Nephrol Dial Transplant 2003; 18: 362-369.
-
(2003)
Nephrol Dial Transplant
, vol.18
, pp. 362-369
-
-
Locatelli, F.1
Canaud, B.2
Giacardy, F.3
-
30
-
-
33845584069
-
Hospital-acquired infections related to contaminated substances
-
Vonberg RP, Gastmeier P. Hospital-acquired infections related to contaminated substances. J Hosp Infect 2007; 65: 15-23.
-
(2007)
J Hosp Infect
, vol.65
, pp. 15-23
-
-
Vonberg, R.P.1
Gastmeier, P.2
-
31
-
-
3242780941
-
Treating anemia early in renal failure patients slows the decline of renal function: A randomized controlled trial
-
Gouva C, Nikolopoulos P, Ioannidis JP et al. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 2004; 66: 753-760.
-
(2004)
Kidney Int
, vol.66
, pp. 753-760
-
-
Gouva, C.1
Nikolopoulos, P.2
Ioannidis, J.P.3
-
32
-
-
14044259130
-
Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: Recommendations for minimization of risk
-
Cournoyer D, Toffelmire EB, Wells GA et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15: 2728-2734.
-
(2004)
J Am Soc Nephrol
, vol.15
, pp. 2728-2734
-
-
Cournoyer, D.1
Toffelmire, E.B.2
Wells, G.A.3
-
33
-
-
23144460027
-
Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: The PROMPT study
-
Provenzano R, Bhaduri S, Singh AK. Extended epoetin alfa dosing as maintenance treatment for the anemia of chronic kidney disease: the PROMPT study. Clin Nephrol 2005; 64: 113-123.
-
(2005)
Clin Nephrol
, vol.64
, pp. 113-123
-
-
Provenzano, R.1
Bhaduri, S.2
Singh, A.K.3
-
34
-
-
27744500483
-
Long-term outcome of individuals with pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: A follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project
-
Bennett CL, Cournoyer D, Carson KR et al. Long-term outcome of individuals with pure red cell aplasia and anti-erythropoietin antibodies in patients treated with recombinant epoetin: a follow-up report from the Research on Adverse Drug Events and Reports (RADAR) Project. Blood 2005; 106: 3343-3347.
-
(2005)
Blood
, vol.106
, pp. 3343-3347
-
-
Bennett, C.L.1
Cournoyer, D.2
Carson, K.R.3
-
35
-
-
0141678217
-
Protocolized anemia management with erythropoietin in hemodialysis patients: A randomized controlled trial
-
Brimble KS, Rabbat CG, McKenna P et al. Protocolized anemia management with erythropoietin in hemodialysis patients: a randomized controlled trial. J Am Soc Nephrol 2003; 14: 2654-2661.
-
(2003)
J Am Soc Nephrol
, vol.14
, pp. 2654-2661
-
-
Brimble, K.S.1
Rabbat, C.G.2
McKenna, P.3
-
36
-
-
0031782623
-
Prospective evaluation of an anemia treatment algorithm in hemodialysis patients
-
Patterson P, Allon M. Prospective evaluation of an anemia treatment algorithm in hemodialysis patients. Am J Kidney Dis 1998; 32: 635-641.
-
(1998)
Am J Kidney Dis
, vol.32
, pp. 635-641
-
-
Patterson, P.1
Allon, M.2
-
37
-
-
0035499472
-
Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit
-
To LL, Stoner CP, Stolley SN et al. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit. Am J Health Syst Pharm 2001; 58: 2061-2065.
-
(2001)
Am J Health Syst Pharm
, vol.58
, pp. 2061-2065
-
-
To, L.L.1
Stoner, C.P.2
Stolley, S.N.3
-
38
-
-
48649091961
-
The impact of a nursing led anemia protocol on hemoglobin and erythropoietin requirements
-
abstract
-
Culleton B, Hemmelgarn B, Hons RB. The impact of a nursing led anemia protocol on hemoglobin and erythropoietin requirements. Am Soc of Nephrol Confer 2003 (abstract).
-
(2003)
Am Soc of Nephrol Confer
-
-
Culleton, B.1
Hemmelgarn, B.2
Hons, R.B.3
|